Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spon...

por Poddubnyy, Denis, Hammel, Ludwig, Heyne, Marvin, Veit, Justyna, Jentzsch, Claudia, Baraliakos, Xenofon
Publicado 2020

Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial

por Venhoff, Nils, Schmidt, Wolfgang A., Lamprecht, Peter, Tony, Hans-Peter, App, Christine, Sieder, Christian, Legeler, Carolin, Jentzsch, Claudia, Thiel, Jens
Publicado 2021

Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial

por Behrens, Frank, Sewerin, Philipp, de Miguel, Eugenio, Patel, Yusuf, Batalov, Anastas, Dokoupilova, Eva, Kleinmond, Christine, Pournara, Effie, Shekhawat, Ankita, Jentzsch, Claudia, Wiedon, Annette, Baraliakos, Xenofon
Publicado 2021

The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy

por Ucar, Ahmet, Gupta, Shashi K., Fiedler, Jan, Erikci, Erdem, Kardasinski, Michal, Batkai, Sandor, Dangwal, Seema, Kumarswamy, Regalla, Bang, Claudia, Holzmann, Angelika, Remke, Janet, Caprio, Massimiliano, Jentzsch, Claudia, Engelhardt, Stefan, Geisendorf, Sabine, Glas, Carolina, Hofmann, Thomas G., Nessling, Michelle, Richter, Karsten, Schiffer, Mario, Carrier, Lucie, Napp, L. Christian, Bauersachs, Johann, Chowdhury, Kamal, Thum, Thomas
Publicado 2012